Compare · LMNX vs WST
LMNX vs WST
Side-by-side comparison of Luminex Corporation (LMNX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMNX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $22.07B.
- Over the past year, LMNX is up 13.3% and WST is up 41.7% - WST leads by 28.3 points.
- WST has hit the wire 4 times in the past 4 weeks while LMNX has been quiet.
- WST has more recent analyst coverage (15 ratings vs 0 for LMNX).
- Company
- Luminex Corporation
- West Pharmaceutical Services Inc.
- Price
- $19.04-1.45%
- $306.12-1.10%
- Market cap
- -
- $22.07B
- 1M return
- -10.23%
- +23.98%
- 1Y return
- +13.33%
- +41.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 15
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest LMNX
- SEC Form 15-12G filed by Luminex Corporation
- SEC Form 4: Eck Stephen L. returned $1,408,701 worth of Common Stock to the company (38,073 units at $37.00) , closing all direct ownership in the company (for withholding tax)
- SEC Form 4: ERICKSON THOMAS W returned $6,932,542 worth of Common Stock to the company (187,366 units at $37.00) , closing all direct ownership in the company to cover taxes
- SEC Form 4: KEVER JIM D returned $8,517,363 worth of Common Stock to the company (230,199 units at $37.00) , closing all direct ownership in the company to satisfy withholding obligation
- SEC Form 4: Lewis Dijuana K returned $257,335 worth of Common Stock to the company (6,955 units at $37.00) , closing all direct ownership in the company
- SEC Form 4: MCNAMARA KEVIN M returned $3,713,616 worth of Common Stock to the company (100,368 units at $37.00) , closing all direct ownership in the company to cover withholding tax
- SEC Form 4: OGUNRO EDWARD A returned $2,253,041 worth of Common Stock to the company (60,893 units at $37.00) , closing all direct ownership in the company to cover taxes
- SEC Form 4: SAMET KENNETH A returned $733,229 worth of Common Stock to the company (19,817 units at $37.00) , closing all direct ownership in the company (withholding tax)
- SEC Form 4: Rew Richard W. II returned $1,760,312 worth of Common Stock to the company (47,576 units at $37.00) , closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: SHAMIR NACHUM returned $8,923,290 worth of Common Stock to the company (241,170 units at $37.00) , closing all direct ownership in the company to cover taxes
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- SEC Form DEFA14A filed by West Pharmaceutical Services Inc.
- SEC Form DEF 14A filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits